XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?

Brendan Coffey, The Motley Fool

Sat, August 1, 2026 astatine 1:17 PM CDT 5 min read

The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers wide vulnerability to the S&P 500 healthcare assemblage astatine a debased cost, whereas the Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) targets a concentrated niche of biotechnology companies.

Choosing betwixt these 2 ETFs involves balancing wide assemblage stableness against the high-growth imaginable of a circumstantial industry. While XLV offers diversified vulnerability to the largest healthcare names successful the S&P 500, PBE utilizes a quantitative attack to people 30 U.S. firms starring the mode successful genomic engineering and biotechnology research. This examination highlights the trade-offs betwixt a low-cost, established money and a much specialized, higher-fee manufacture play.

Snapshot (cost & size)

Beta measures terms volatility comparative to the S&P 500; beta is calculated from monthly returns implicit the disposable money past (up to 5 years). The 1-yr instrumentality represents full instrumentality implicit the trailing 12 months. Dividend output is the trailing-12-month organisation output arsenic of the adjacent of trading connected July 30.

The State Street money is importantly much affordable for semipermanent holders, featuring an disbursal ratio of 0.08%. In contrast, the Invesco money carries a 0.58% disbursal ratio, reflecting the higher costs associated with its much active, dynamic indexing strategy. Yields are comparable, arsenic some funds presently administer betwixt 1.6% and 1.7%.

Performance & hazard examination

What's wrong

State Street Health Care Select Sector SPDR ETF provides vulnerability to 60 holdings, each of which are classified arsenic healthcare stocks. Its largest positions see Eli Lilly & Co (NYSE:LLY) astatine 16.5%, Johnson & Johnson (NYSE:JNJ) astatine 10.6%, and AbbVie (NYSE:ABBV) astatine 7.7%. It was launched successful 1998. State Street Health Care Select Sector SPDR ETF has paid $2.53 per stock implicit the trailing 12 months, which connected its caller ~$163.52 stock terms works retired to a 1.6% yield.

Invesco Biotechnology & Genome ETF is simply a much focused vehicle, holding 30 U.S. companies, each besides successful the healthcare sector. Its largest positions see Vertex Pharmaceuticals (NASDAQ:VRTX) astatine 5.2%,  Biogen Inc (NASDAQ:BIIB) astatine 5.1%, and Amgen Inc (NASDAQ:AMGN) astatine 4.9%. It was launched successful 2005. Invesco Biotechnology & Genome ETF has paid $1.55 per stock implicit the trailing 12 months, which connected its caller ~$91.10 stock terms works retired to a 1.7% yield.